Xlife Sciences AG (XLS) - Net Assets
Based on the latest financial reports, Xlife Sciences AG (XLS) has net assets worth CHF372.36 Million CHF (≈ $470.76 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CHF517.12 Million ≈ $653.78 Million USD) and total liabilities (CHF144.76 Million ≈ $183.01 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check XLS strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CHF372.36 Million |
| % of Total Assets | 72.01% |
| Annual Growth Rate | 25.04% |
| 5-Year Change | 76.28% |
| 10-Year Change | N/A |
| Growth Volatility | 17.78 |
Xlife Sciences AG - Net Assets Trend (2019–2025)
This chart illustrates how Xlife Sciences AG's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Xlife Sciences AG stock valuation.
Annual Net Assets for Xlife Sciences AG (2019–2025)
The table below shows the annual net assets of Xlife Sciences AG from 2019 to 2025. Also explore XLS shareholders equity momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CHF372.36 Million ≈ $470.76 Million |
+21.98% |
| 2024-12-31 | CHF305.26 Million ≈ $385.93 Million |
+13.83% |
| 2023-12-31 | CHF268.17 Million ≈ $339.04 Million |
+14.00% |
| 2022-12-31 | CHF235.23 Million ≈ $297.40 Million |
+11.36% |
| 2021-12-31 | CHF211.23 Million ≈ $267.06 Million |
+62.28% |
| 2020-12-31 | CHF130.17 Million ≈ $164.57 Million |
+33.68% |
| 2019-12-31 | CHF97.38 Million ≈ $123.11 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Xlife Sciences AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 123.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CHF308.08 Million | 107.52% |
| Total Equity | CHF286.53 Million | 100.00% |
Xlife Sciences AG Competitors by Market Cap
The table below lists competitors of Xlife Sciences AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Genohco Inc.
KQ:361390
|
$79.92 Million |
|
Richmond International Travel & Tours Co Ltd
TWO:2743
|
$79.94 Million |
|
Suprema HQ Inc
KQ:094840
|
$79.94 Million |
|
The Intergroup Corporation
NASDAQ:INTG
|
$80.00 Million |
|
JHM Consolidation Bhd
KLSE:0127
|
$79.88 Million |
|
Klevo Rewards Limited
AU:KLV
|
$79.87 Million |
|
Unitech Electronics Co. Ltd.
TW:3652
|
$79.85 Million |
|
Quantum Graphite Ltd
AU:QGL
|
$79.84 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Xlife Sciences AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 305,260,120 to 286,528,821, a change of -18,731,299 (-6.1%).
- Net loss of 21,547,312 reduced equity.
- New share issuances of 3,060,000 increased equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CHF-21.55 Million | -7.52% |
| Share Issuances | CHF3.06 Million | +1.07% |
| Other Changes | CHF-243.99K | -0.09% |
| Total Change | CHF- | -6.14% |
Book Value vs Market Value Analysis
This analysis compares Xlife Sciences AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.26x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.50x to 0.26x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CHF25.89 | CHF12.85 | x |
| 2020-12-31 | CHF31.31 | CHF12.85 | x |
| 2021-12-31 | CHF41.75 | CHF12.85 | x |
| 2022-12-31 | CHF44.52 | CHF12.85 | x |
| 2023-12-31 | CHF47.95 | CHF12.85 | x |
| 2024-12-31 | CHF53.16 | CHF12.85 | x |
| 2025-12-31 | CHF49.68 | CHF12.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Xlife Sciences AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -7.52%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -7826.48%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.80x
- Recent ROE (-7.52%) is below the historical average (8.31%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 1.08% | 203.99% | 0.00x | 1.58x | CHF-8.69 Million |
| 2020 | 16.49% | 5408.40% | 0.00x | 1.43x | CHF8.44 Million |
| 2021 | 25.29% | 6627.03% | 0.00x | 2.27x | CHF32.30 Million |
| 2022 | 6.08% | 1392.26% | 0.00x | 2.08x | CHF-9.21 Million |
| 2023 | 5.55% | 1505.33% | 0.00x | 1.91x | CHF-11.94 Million |
| 2024 | 11.23% | 4105.60% | 0.00x | 1.77x | CHF3.75 Million |
| 2025 | -7.52% | -7826.48% | 0.00x | 1.80x | CHF-50.20 Million |
Industry Comparison
This section compares Xlife Sciences AG's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $342,766,129
- Average return on equity (ROE) among peers: -26.04%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Xlife Sciences AG (XLS) | CHF372.36 Million | 1.08% | 0.39x | $79.88 Million |
| Addex Therapeutics Ltd (ADXN) | $64.41 Million | -52.23% | 0.15x | $3.89 Million |
| Bachem Holding AG (BANB) | $1.46 Billion | 10.20% | 0.45x | $5.42 Billion |
| BB Biotech AG (BION) | $2.78 Billion | 20.81% | 0.00x | $2.93 Billion |
| Bioversys AG (BIOV) | $10.68 Million | -175.24% | 2.27x | $160.82 Million |
| Basilea Pharmaceutica AG (BSLN) | $125.38 Million | -47.04% | 0.20x | $686.09 Million |
| Idorsia Ltd (IDIA) | $-1.14 Billion | 0.00% | 0.00x | $1.03 Billion |
| MINDMAZE THERAPEUTICS HOLDING SA (MMTX) | $86.00K | -1.16% | 0.08x | $29.57 Million |
| Molecular Partners AG (MOLN) | $135.79 Million | -13.71% | 0.36x | $145.86 Million |
| Newron Pharmaceuticals SpA (NWRN) | $-29.91 Million | 0.00% | 0.00x | $243.84 Million |
| Relief Therapeutics Holding AG (RLF) | $21.28 Million | -2.05% | 0.67x | $36.33 Million |
About Xlife Sciences AG
Xlife Sciences AG focuses on the development and commercialization of research projects in the life sciences sector. The company's project covers technology platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health areas that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data; and offers clinica… Read more